Abstract
DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.
| Original language | English |
|---|---|
| Pages (from-to) | 134-139 |
| Number of pages | 6 |
| Journal | British Journal of Diabetes and Vascular Disease |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 May 2007 |
Keywords
- DPP-4
- Gliptin
- Incretin
- Inhibitor
- Sitagliptin
- Type 2 diabetes
Fingerprint
Dive into the research topics of 'Sitagliptin - Enhancing incretin action'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver